Project: Treating cancer by targeting endogenous retroviral fossils encoded within the human genome.
| Acronym | TREATCANCERV (Reference Number: 113556) |
| Duration | 01/01/2020 - 03/01/2023 |
| Project Topic | We want to translate broad and curative anticancer efficacy against murine endogenous retrovirus (ERVs) envelope (Env) and particle genes, into treatments against human ERV (HERVs) expressing cancers. The deliverable will be human ex vivo and murine in vivo validated novel Virus-Like-Vaccine (VLV) candidates and monoclonal antibodies capable of blocking the immunosuppressive domain of cancer expressed ERV Envs. These candidates will be ready for clinical development (GMP/TOX) after the project. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 11 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | InProTher Aps | Coordinator | Denmark |
| 2 | Sirion Biotech GmbH | Partner | Germany |
| 3 | Københavns Universitet | Partner | Denmark |
| 4 | Universität Regensburg | Partner | Germany |